Under construction – not a live service
Sign in
Taking people in IranPhase 2

Tests natural killer cell injections in people with high-grade brain tumors

Tests injected natural killer immune cells in people with high-grade glioma brain tumors.

Plain-language title generated from the registry record
Registry title: Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

Key facts

Where
Tehran, IranSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a newly diagnosed grade 3 or 4 brain tumor (glioma). They would receive an injection of donor natural killer cells into the spinal fluid.

Age
The criteria say 3 to 60 years old; the registry header lists 3 to 70 years.
Sex
Both sexes can join.
Disease stage
Newly diagnosed grade 3 or 4 brain tumor (WHO classification): IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, IDH-wild type glioblastoma, diffuse midline glioma, diffuse hemispheric glioma, or diffuse pediatric-type high-grade glioma, IDH-wild type.
Earlier treatment
The record does not name a required earlier treatment. It excludes people with a history of other cancers.
Biomarker or test result
The tumor type is defined by IDH status (mutant or wild type). Blood counts and liver, kidney and clotting tests must be within the set limits, and the Lansky/Karnofsky performance score must be above 60.

Main reasons for not taking part

  • Signs of radio necrosis on MRI or MRS
  • Cannot tolerate the new treatment because of an emergency condition
  • History of other cancers
  • Any immune deficiency or condition that weakens the immune system
  • Pregnancy

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 70 years old?

Source: NCT06687681, who can take part

Where in Iran

  • Rasoul Akram hospitalTehran, IranContact: Mohammad Faranoush, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Marzieh Ebrahimi
Trial code
NCT06687681
Record updated
9 April 2025
Original description
Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults. Surgical removal and tumor resection are the primary treatment approaches for gliomas. In such cases, whole-brain radiation therapy is also employed as a therapeutic option, which itself has significant side effects, and studies have shown limited impact on improving patient survival. Targeted therapy and recently investigated approaches such as targeted therapy have shown some tumor regression, but in most cases, tumor recurrence has been observed after initial regression. Therefore, they have a limited impact on prolonging patient survival. Immunotherapy, particularly immunotherapy with specific immune cells, can effectively identify and eliminate cancer cells and has been utilized as a new approach in the past two decades, especially in cancers where conventional methods have limited success. Among the effective immunotherapy methods, using natural killer cells (NK cells) can be one of the promising approaches. Currently, phase I clinical trials have been conducted by our research group in patients with gliomas.Read full original descriptionShow less

Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial

Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults. Surgical removal and tumor resection are the primary treatment approaches for gliomas. In such cases, whole-brain radiation therapy is also employed as a therapeutic option, which itself has significant side effects, and studies have shown limited impact on improving patient survival. Targeted therapy and recently investigated approaches such as targeted therapy have shown some tumor regression, but in most cases, tumor recurrence has been observed after initial regression. Therefore, they have a limited impact on prolonging patient survival. Immunotherapy, particularly immunotherapy with specific immune cells, can effectively identify and eliminate cancer cells and has been utilized as a new approach in the past two decades, especially in cancers where conventional methods have limited success. Among the effective immunotherapy methods, using natural killer cells (NK cells) can be one of the promising approaches. Currently, phase I clinical trials have been conducted by our research group in patients with gliomas.

Exclusion: -.

ClinicalTrials.gov NCT06687681